UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Annals of oncology, 2014-12, Vol.25 (12), p.2357-2362

2014

Volltextzugriff (PDF)

Endocrine therapy: is the first generation of targeted drugs the last?

Journal of internal medicine, 2013-08, Vol.274 (2), p.144-152

Pritchard, K. I.

2013

Volltextzugriff (PDF)

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of oncology, 2014-04, Vol.25 (4), p.808-815

2014

Volltextzugriff (PDF)

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy

Annals of oncology, 2014-05, Vol.25 (5), p.992-998

2014

Volltextzugriff (PDF)

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

European journal of cancer (1990), 2017-11, Vol.85, p.146-154

2017

Volltextzugriff (PDF)

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study

Supportive care in cancer, 2019-08, Vol.27 (8), p.3035-3043

2019

Volltextzugriff (PDF)

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

JNCI : Journal of the National Cancer Institute, 2009-05, Vol.101 (9), p.644-650

2009

Volltextzugriff (PDF)

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study

Breast cancer research and treatment, 2018-10, Vol.171 (3), p.709-717

2018

Volltextzugriff (PDF)

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab

Breast cancer research and treatment, 2018-07, Vol.170 (1), p.169-177

2018

Volltextzugriff (PDF)

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Annals of oncology, 2013-02, Vol.24 (2), p.355-361

2013

Volltextzugriff (PDF)

Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)

Annals of oncology, 2013-08, Vol.24 (8), p.1986-1993

2013

Volltextzugriff (PDF)

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5542-5551

2005

Volltextzugriff (PDF)

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

The Lancet (British edition), 2008, Vol.371 (9606), p.29-40

2008

Volltextzugriff (PDF)

Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study

Journal of clinical oncology, 2003-03, Vol.21 (5), p.843-850

2003

Volltextzugriff (PDF)

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

Breast cancer research and treatment, 2011-07, Vol.128 (2), p.401-409

2011

Volltextzugriff (PDF)

Risk of Menopause During the First Year After Breast Cancer Diagnosis

Journal of clinical oncology, 1999-08, Vol.17 (8), p.2365-2370

1999

Volltextzugriff (PDF)

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

Annals of oncology, 2002-01, Vol.13 (1), p.12-15

2002

Volltextzugriff (PDF)

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)

Annals of oncology, 2010-02, Vol.21 (2), p.283-290

2010

Volltextzugriff (PDF)

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.143-151

2013

Volltextzugriff (PDF)

Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis

Breast cancer research and treatment, 2018-04, Vol.168 (2), p.299-310

2018

Volltextzugriff (PDF)

Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8

Journal of clinical oncology, 2000-06, Vol.18 (12), p.2385-2394

2000

Volltextzugriff (PDF)

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Annals of oncology, 2008-05, Vol.19 (5), p.877-882

2008

Volltextzugriff (PDF)

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Annals of oncology, 2010-06, Vol.21 (6), p.1246-1253

2010

Volltextzugriff (PDF)

Is tamoxifen effective in prevention of breast cancer?

The Lancet (British edition), 1998-07, Vol.352 (9122), p.80-81

Pritchard, Kathleen I

1998

Volltextzugriff (PDF)

Trends in endocrine therapy and chemotherapy for early breast cancer : a focus on the premenopausal patient

Journal of cancer research and clinical oncology, 2006-05, Vol.132 (5), p.275-286

2006

Volltextzugriff (PDF)

1 – 25 von 3.408

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.013)
Mit Volltextzugriff
(2.758)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(3.391)
Deutsch
(3)
Japanisch
(2)
Spanisch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.110)
Life Sciences & Biomedicine
(1.611)
Humans
(1.132)
Female
(670)
Biological And Medical Sciences
(615)
Male
(481)
Medical Sciences
(431)
Animals
(373)
Oncology
(373)
Physical Sciences
(361)
Adult
(307)
Middle Aged
(297)
Agriculture
(223)
Fundamental And Applied Biological Sciences. Psychology
(208)
Aged
(200)
Genetics & Heredity
(174)
Chemistry
(158)
Child
(158)
Physics
(155)
Tumors
(149)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.529)
MEDLINE
(1.475)
IngentaConnect
(1.181)
Journals@Ovid Complete
(1.129)
Single Journals
(1.046)
ScienceDirect Journals (5 years ago - present)
(556)
Wiley Online Library Journals Frontfile Complete
(443)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(429)
IngentaConnect Journals
(420)
Wiley Online Library Full Collection 2018
(310)
Oxford journals
(193)
JSTOR
(181)
Springer journals
(177)
Nature Journals Online
(176)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(128)
Psychology & Behavioral Sciences Collection
(110)
Nexis Uni
(110)
Ebook Central Perpetual and DDA
(104)
eBooks on EBSCOhost
(94)
Springer Book Series
(91)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Endocrine therapy: is the first generation of targeted drugs the last?

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC)

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

Risk of Menopause During the First Year After Breast Cancer Diagnosis

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis

Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Activity of fulvestrant in HER2-overexpressing advanced breast cancer

Is tamoxifen effective in prevention of breast cancer?

Trends in endocrine therapy and chemotherapy for early breast cancer : a focus on the premenopausal patient

Suchergebnisse filtern